Background--We have demonstrated that tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2), a scaffolding protein common to TNF receptors 1 and 2, confers cytoprotection in the heart. However, the mechanisms for the cytoprotective effects of TRAF2 are not known.
M yocardial reperfusion after a period of ischemia may be regarded as a "mixed blessing." That is, on the one hand, there is the clear-cut benefit that occurs as the result of recovery of heart muscle that attends reperfusion; however, on the other hand, there are also deleterious reperfusion-dependent effects that can be attributed to excessive activation of proinflammatory cytokines. Although excessive activation of proinflammatory cytokines may be overtly deleterious by producing left ventricular (LV) dysfunction and increased tissue destruction attributable to robust inflammatory response, there is increasing evidence that activation of proinflammatory cytokines may be beneficial by upregulating cytoprotective pathways, as well as by promoting tissue repair. Indeed, we and others have suggested that proinflammatory cytokines belonging to a phylogenetically conserved host defense system, collectively referred to as innate immunity, may be beneficial by upregulating cytoprotective pathways, as well as by promoting tissue repair. [1] [2] [3] [4] Both gain-and loss-offunction studies have suggested an important role for tumor necrosis factor (TNF) with respect to mediating myocardial cytoprotection in vitro, 5 ex vivo, 2, 4, 6, 7 as well as in vivo. [8] [9] [10] Moreover, TNF has been implicated as a mediator of classic ischemic preconditioning, through a signal transducer and activator of transcription 3-dependent pathway (SAFE pathway). 4 We have shown, through a variety of experimental approaches, that signaling through the type 1 (TNFR1) and type 2 (TNFR2) TNF receptors is sufficient to mimic the effects of TNF in vitro and ex vivo. 5, 11 Although it is conceivable that TNFR1 and TNFR2 activate disparate cytoprotective signal transduction pathways, the most parsimonious explanation is that TNFR1 and TNFR2 transduce a common cytoprotective repertoire in the heart. Noting that the intracellular scaffolding protein, TNFR-associated factor 2 (TRAF2) was common to both TNFR1 and TNFR2, and recognizing that TRAF2 mediates cytoprotection in nonmyocyte cell types, 12 we reasoned that the cytoprotective effects of TNF in the heart were mediated, at least in part, through TRAF2. To this end, we generated lines of mice with low levels of TRAF2 expression in the heart (MHC-TRAF2 LC ) and demonstrated that these mice had significantly improved LV functional recovery and significantly less LV tissue injury after ischemia-reperfusion (I/R) injury, when compared to littermate (LM) control mice.
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To extend our initial observations with respect to the cytoprotective role of TRAF2 in the heart, here we generate lines of mice with a cardiac-restricted dominant negative form of TRAF2 (MHC-TRAF2 DN ). Notably, hearts from MHC-TRAF2 DN mice demonstrated an I/R injury-induced phenotype that was opposite to the MHC-TRAF2 LC mice, namely, increased membrane permeability, increased creatine kinase (CK) release, and significantly worse LV functional recovery after reperfusion. Transcriptional profiling of MHC-TRAF2 LC and MHC-TRAF2 DN mice and subsequent functional studies in mice identified dysferlin, a calcium-triggered exocytotic membrane repair protein, as a novel cytoprotective gene that mediates the cytoprotective effects of TRAF2-mediated signaling in the mammalian heart.
Methods

Generation and Characterization of Transgenic and Knockout Mice
MHC-TRAF2 DN Transgenic Mice
Mice with cardiac-restricted expression of dominant negative TRAF2 (MHC-TRAF2 DN ) were generated using a dominant negative TRAF2 construct (a generous gift from Dr Yongwon Choi 13 ), in which the N-terminal domain of TRAF2 (TRAF2 ) lacking the N-terminal ring and zinc fingers essential for TRAF2-mediated nuclear factor kappa B (NF-jB)-and c-Jun Nterminal kinase (JNK)-mediated signaling was deleted. Briefly, the TRAF2 D241-501 mutant construct was inserted behind the myosin heavy chain (aMHC) promoter, which was obtained from Dr Jeff Robbins. The TRAF2 DN transgene constructs were injected into single-cell embryos of Friend virus B (FVB) mice at the Transgenic Core Facility at Baylor College of Medicine, as previously described. 11 Founder lines were identified by Southern blotting, as described above. 11 Age-matched LM mice that lacked the transgene were used as appropriate controls. Hemizygous MHC-TRAF2 DN mouse lines were characterized at 12 weeks of age using standard morphological and histological analyses, as well as two-dimensional (2D)-targeted M-mode echocardiography (Echo), as previously described. 11 Further characterization of MHC-TRAF2 DN mice was performed by examining activation of NF-jB in nuclear extracts obtained from hearts of 12-week na€ ıve MHC-TRAF2 DN and LM control mice. Electrophoretic mobility shift assays (EMSAs) were performed, as previously described, 11 using an NF-jB oligonucleotide consensus sequence (5 0 
MHC-TRAF2 LC Transgenic Mice
The hemizygous line of transgenic (Tg) mice with cardiacrestricted overexpression of low levels of TRAF2 (referred to as MHC-TRAF2 LC ) have been described elsewhere in detail (FVB background). 11 Briefly, MHC-TRAF2 LC hearts have improved LV functional recovery, decreased myocardial CK release, and decreased uptake of Evans blue dye after I/R injury ex vivo, when compared to LM controls. ; Stock No. 006830; Bar Harbor, ME). The lines of 129S1/SvImJ (129) wild-type (WT) mice that were used as the appropriate controls (http:// jaxmice.jax.org/strain/002448.html) were also purchased from The Jackson Laboratory (129; Stock No. 0024480). Dysferlin À/À mice were characterized at 12 weeks of age using standard morphological and histological analyses, as well as 2D-targeted M-mode ECG, as previously described.
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LV function was assessed ex vivo in 12-week dysferlin À/À and WT mouse hearts using a buffer-perfused Langendorff apparatus, as previously described. 15 to yield a pH of 7.4 (37°C). A hand-made balloon was inserted into the LV and connected to a pressure transducer (ML844; ADInstruments, Colorado Springs, CO). The balloon was inflated with water to adjust LV end-diastolic pressure (LVEDP) at 5 to 10 mm Hg. All hearts were paced at 420 bpm with pacing electrodes placed on the right atrium. After a 20-minute stabilization period, hearts were subjected to no-flow ischemia (t=0 minutes) for 30 minutes, followed by reperfusion (t=30 minutes) for up to 60 minutes (t=90 minutes). Functional data were recorded at 1 kHz on a data acquisition system (PowerLab; ADInstruments). LV developed pressure (LVDP) was calculated as the difference between peak systolic pressure and LVEDP, and the resulting LV functional recovery data are expressed as the percentage of LVDP at baseline.
MHC-TRAF2 LC /Dysferlin-Null Mice
Assessment of Cardiac Myocyte Injury After I/R Injury
To assess the effects of I/R injury on cardiac myocyte injury in MHC-TRAF2 DN , MHC-TRAF2 LC , 16 we used Evans blue dye uptake to assess the degree of myocardial tissue injury after I/R injury, as previously described. 11 Briefly, Evans blue dye crosses into cells with permeable membranes and accumulates in myofibrils, where it emits red autofluorescence when examined using fluorescence microscopy. Fluorescence microscopy (9200) was performed using a filter set with an excitation of 510 to 560 nm and an emission of 590 nm in order to assess the amount of Evans blue dye uptake in the myocardium at baseline and after I/R injury. Hearts were examined at the level of the papillary muscle, using a total of 30 microscopic fields per heart. Data are expressed as the percent area of the myocardium with red fluorescence. BeadChips contain sequences representing %46 000 curated genes and expressed sequence tags (ESTs). After scanning the probe array, the resulting image was analyzed using BeadStudio software (Illumina). Samples were normalized using a cubic spline procedure. Differentially expressed genes between MHC-TRAF2 LC and MHC-TRAF2 DN and LM controls were determined using an ANOVA test with contrasts using Partek GS (Partek, St. Louis, MO) using an unadjusted P value <0.05 and a fold change of 1.2 or greater. Agglomerative hierarchical clustering (combination of two rows/columns or clusters at each step of the procedure) was also performed using Partek GS. Euclidean distance was used to measure dissimilarity (the distance between two rows or columns), and average linkage (the average distance between all pairs of objects in two different clusters) was used as the measure of distance between two clusters. An analysis of gene expression in relation to cellular components was performed using the Database for Annotation Visualization and Integrated Discovery (http://david.abcc.ncifcrf.gov/), 17 according to the classification of cellular components assigned by the Gene Ontology (GO) Consortium.
Dysferlin mRNA and Protein Expression in MHC-TRAF2 LC and MHC-TRAF2 DN Hearts
Dysferlin mRNA levels were determined in 12-week hearts from MHC-TRAF2 LC , MHC-TRAF2 DN , and LM control mice by realtime quantitative polymerase chain reaction (RT-qPCR), using an ABI 7500 Fast Real-Time quantitative PCR System (Applied Biosystems, Foster City, CA). Two micrograms of total RNA was reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNAs were amplied for 18S rRNA (Part No.: 4333760F) and dysferlin (Assay ID No.: Mm00458042_m1) using the TaqMan gene expression assay (Applied Biosystems), and the final results represent the fold change relative to LM controls using the DDCt method with normalization to 18s expression. Dysferlin protein levels were determined in membrane preparations obtained from 12-week-old MHC-TRAF2 LC , MHC-TRAF2 DN , and LM control mice. Briefly, LV tissue was homogenized in isotonic sucrose buffer containing (in mmol/L): 20.0 Tris-HCl, 250.0 sucrose, 1 Na 3 VO 4 , 2.0 MgCl 2 , 2.0 EDTA, 0.5 EGTA, 2.0 phenylmathanesulfonyl fluoride, and 1.0 dithiothreitol and 0.02% (vol/vol) protease inhibitor cocktail (pH 7.4). Homogenates were centrifuged at 100 000g for 60 minutes at 4°C to separate the particulate fraction from the cytosolic fraction, and the resulting pellet was resonicated in sucrose buffer containing 0.1% Triton X-100 and centrifuged at 100 000g for 30 minutes at 4°C. Equivalent amounts (50 lg) of supernatant protein were separated on a 10% SDS-PAGE and transferred to nitrocellulose membranes. Western blot analysis was performed using rabbit anti-dysferlin (1:1000; Epitomics, Burlingame, CA), followed by a peroxidase-labeled secondary antibody (1:3000; Cell Signaling). Antigen-antibody complexes were visualized by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech, Piscataway, NJ). Membranes were incubated at 70°C for 10 minutes in stripping buffer and then reprobed for rabbit anti-calsequestrin (1:1000; Abcam, Cambridge, MA). Original films were exposed to ECL (Hyperfilm TM , ECL TM ; Amersham Pharmacia Biotech), and band density was determined (in arbitrary units) using the software, ImageJ (NIH). Dysferlin protein levels were normalized by calsequestrin levels to account for any potential loading differences.
NF-jB-Induced Activation of Dysferlin Gene Expression
Previous studies from this laboratory have suggested that TNF-TRAF2-mediated activation of NF-jB is responsible for provoking cytoprotective responses in the heart after I/R injury. 11 To determine whether NF-jB was involved in upregulation of dysferlin in MHC-TRAF2 LC mouse hearts, we performed a chromatin immunoprecipitation (ChIP) assay using the EZ-ChIP Assay Kit (Millipore, Temecula, CA), following the manufacturer's instructions. Briefly, mouse hearts were minced and incubated in PBS containing 1% formaldehyde at room temperature for 10 minutes to cross-link proteins to DNA. To determine whether I/R injury resulted in differential localization of dysferlin in cardiac myocytes from MHC-TRAF LC mouse hearts, compared to LM controls, we performed immunohistochemical (IHC) staining at baseline and after 60 minutes of I/R injury. Briefly, hearts were subjected to the I/R protocol exactly as described above and were then perfuse fixed with Z-fix (Anatech, Battle Creek, MI). Antigen retrieval was performed by placing slides in retrieval buffer (180 lmol/L citric acid, 820 lmol/L sodium citrate) and heating in a microwave 39 for 4 minutes. Tissue was then permeabilized using 19 TBS/0.1% Triton X-100 for 20 minutes at room temperature. After permeabilization, tissue was blocked in a buffer containing 109 blocking reagent (Roche, Indianapolis, IN), 9 mL FCS, and 27 maleate buffer (100 mmol/L maleic acid, 150 mmol/L NaCl; pH 7.5) for 30 minutes at room temperature. A primary rabbit antidysferlin monoclonal antibody (Romeo; Epitomics, Burlingame, CA) was applied overnight at 4°C (1:50 dilution in blocking buffer). Slides were washed with 19 TBS/0.1% Tween 39 5 minutes each and labeled with a red fluorescence-conjugated anti-rabbit secondary antibody (Alexa Fluor 647; Life Technologies, Carlsbad, CA) for 1 hour at room temperature (1:500 dilution in blocking buffer). Slides were washed with TBS/0.1% Tween, mounted with Vectashield containing 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA), and imaged using a Zeiss confocal (LSM 700 Laser Scanning Confocal; Carl Zeiss GmbH, Jena, Germany) microscope using DAPI and Alexa Fluor 647 filters.
Statistical Analysis
Data are expressed as meanAESEM. Two-way repeatedmeasures ANOVA was used to test for differences in percent LVDP between groups as a function of time after I/R injury between groups. Post-hoc ANOVA testing was performed, where appropriate, using Fisher's least significant difference test. 18 CK release, the area of the myocardium (%) with Evans blue uptake after I/R injury, dysferlin mRNA and protein levels, and heart weight/body weight ratios were examined using a nonpaired t test. All data were tested for normality before performing parametric testing. Significant differences were said to exist at P<0.05.
Results
Generation Figure 1A ), as well as by assessment of heart weight/body weight ratio ( Figure 1B) , and 2D ECG assessment of LV structure (Figure 2A through 2C Specificity of DNA-protein-binding nuclear extracts was determined using a 209 molar excess of the respective unlabeled oligonucleotide. D, JNK activation assay in LM and TRAF2 DN hearts (12 weeks) at baseline and after I/R injury. BW indicates body weight; HW, heart weight; I/R, ischemia-reperfusion; JNK, c-Jun N-terminal kinase; MHC, myosin heavy chain; NF-jB, nuclear factor kappa B; TRAF2, tumor necrosis factor receptor-associated factor 2.
Effects of Cardiac-Restricted Overexpression of Dominant Negative TRAF2 After I/R Injury
To determine the effects of loss of TRAF2-mediated signaling after I/R injury, we subjected MHC-TRAF2 DN mice to 30 minutes of no-flow ischemia, followed by 60 minutes of reperfusion. The salient finding shown by Figure 3A is that hearts from MHC-TRAF2 DN mice had significantly worse LV functional recovery at 10 to 60 minutes (P<0.05/time point) after reperfusion, when compared to the LM control mice. To determine whether the decreased functional recovery of MHC-TRAF2 DN mice was the result of increased myocyte injury, we measured CK release and Evans blue dye uptake 30 minutes after reperfusion. As shown in Figure 3B , there was a significant (P<0.05) 1.4-fold increase in CK release after I/R injury in MHC-TRAF2 DN hearts, when compared to LM control hearts. Consistent with these findings, there was a significant (P<0.05) increase in Evans blue dye uptake in MHC-TRAF2 DN mouse hearts, as depicted by the representative fluorescence photomicrographs shown in Figure 3C and the group data summarized in Figure 3D . In contrast, hearts from MHC-TRAF2 LC mice that were subjected to I/R injury demonstrated significantly improved LV functional recovery 10 to 60 minutes (P<0.05/time) after IR injury, compared to LM controls, consistent with our earlier observations.
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Viewed together, these results suggest that low levels of myocardial TRAF2 are sufficient to protect cardiac myocytes against I/R injury, whereas loss of TRAF2-mediated signaling in cardiac myocytes leads to increased cardiac myocyte injury and decreased functional recovery after I/R injury.
Transcriptional Profiling in MHC-TRAF2 LC and MHC-TRAF2 DN Hearts
To explore the potential mechanisms responsible for the cytoprotective effects of TRAF2 in the adult heart, we performed transcriptional profiling in 12-week-old na€ ıve LM, MHC-TRAF2 LC , and MHC-TRAF2 DN hearts. Transcriptional profiling revealed that there were 1059 upregulated genes and 1199 downregulated genes in MHC-TRAF2 LC hearts, in comparison to LM controls, whereas MHC-TRAF2 DN hearts had 965 upregulated genes and 1089 downregulated genes, in comparison to LM controls ( Figure 4A and 4B). Agglomerative hierarchical clustering of these transcriptional profiles showed that gene expression profiles in the MHC-TRAF2 LC and MHC-TRAF2 DN mouse hearts clustered differently than those in LM control hearts ( Figure 5 ), suggesting that gain and loss of TRAF2 signaling in the heart results in discordant changes in gene expression relative to WT levels of TRAF2 signaling. Moreover, gene expression profiles of MHC-TRAF2 DN hearts clustered with LM control hearts. Based upon the functional studies shown in Figure 3 , which suggested that gain and loss of function of TRAF2 signaling led, respectively, to improved and worsened responses to I/R injury, as well as the transcriptional profiling studies, which suggested that MHC-TRAF2 DN and the MHC-TRAF2 LC mouse hearts had distinct gene profiles, we focused our search for potential candidate cytoprotective genes on those genes whose expression level (relative to LM) was discordant (opposite) in MHC-TRAF2 DN and in the MHC-TRAF2 LC mouse hearts. Figure 4 shows that there were 94 discordant genes that were upregulated in MHC-TRAF2 LC mice and downregulated in MHC-TRAF2 DN mice (referred to as "Up/Down"; Figure 4A ), and there were 110 discordant genes that were downregulated in MHC-TRAF2 LC mice and upregulated in MHC-TRAF2 DN mice (referred to as "Down/Up"; Figure 4B ). Of the 94 discordant genes identified in the Up/Down group, there were 25 expressed sequence tags (ESTs) and 69 known genes. Of the 110 discordant genes in the Down/Up group, there were 31 ESTs and 79 known genes (see Table 1 ). We then performed a GO analysis of cellular components on the 148 genes identified in the Up/Down and Down/Up groups. As shown in Figure 4C , the cellular components that were enriched (greatest to least) included cytoplasm (P=0.047910 À4 ), mitochondrion (P=0.025910 À4 ), plasma membrane (P=0.047), cytoskeleton (P=0.052), endosome (P=0.014), and nucleus (P=0.09). Given that our results implicated TRAF2 signaling with preservation of membrane integrity after I/R injury ( Figure 3C and 3D), as well as previous in vitro studies from this laboratory, which demonstrated that TNFR1-and TNFR2-mediated signaling preserved sarcolemmal integrity after hypoxia reoxygenation injury, 5 we focused our search on genes in the plasma membrane gene cluster. Table 2 depicts those discordantly regulated genes in MHC-TRAF2 DN and MHC-TRAF2 LC mouse hearts that were identified in the plasma membrane gene cluster. An expanded Table 3 . Inspection of Table 3 reveals that there were clusters of genes involved in the cytoskeleton/integrins (ENAH, ITGB5, VASP, RALB, ITGB1, DST, and SYNC), ion channels (KCNH2, KCNB1), energetics (ATP1B1), cell death (FKBP8, RHOB, and MFGE8), membrane trafficking (DYS, MSN, RAB11A, and RAB3A), and cell signaling (PPP1R9B, PLXND, EPS15, CAMK2N1, ATF6B, ASAH2, and CISH). Of these potential candidate genes, dysferlin was of particular interest because of its role in maintaining sarcolemmal integrity through exocytotic membrane "patch" repair. 20 We therefore focused on the potential role of dysferlin in TRAF2-mediated cytoprotection.
To confirm results with respect to the dysferlin gene array transcriptional profiling studies, we performed RT-qPCR and Western blot analysis in hearts of LM, MHC-TRAF2 DN , and MHC-TRAF2 LC mouse hearts. As shown in Figure 6A , mRNA levels of dysferlin were significantly increased (P<0.05) in MHC-TRAF2 LC hearts, compared to LM controls. Although there was a decrease in dysferlin mRNA in MHC-TRAF2 DN hearts, when compared to LM controls, this change was not significantly statistically (P=0.09). Importantly, Western blot analysis demonstrated that membrane protein levels of dysferlin were 1.8-fold upregulated (P<0.0001) in MHC-TRAF2 LC hearts and downregulated 0.7-fold (P<0.05) in MHC-TRAF2 DN hearts, compared to respective LM controls ( Figure 6B ). Accordingly, we focused subsequent studies on This is the noncatalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. The beta subunit regulates, through assembly of alpha/beta heterodimers, the number of sodium pumps transported to the plasma membrane.
ATP biosynthetic process (GO:0006754); response to hypoxia (GO:0001666); transport (GO:0006810)
ITGB5
Integrin beta-5 Integrin alpha-V/beta-5 is a receptor for fibronectin. It recognizes the sequence R-G-D in its ligand.
Cell-matrix adhesion (GO:0007160); integrin-mediated signaling pathway 
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ITGB1
Integrin beta-1 Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/ beta-1, and alpha-11/beta-1 are receptors for collagen. Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/ beta-1, alpha-10/beta-1, alpha-11/beta-1, and alpha-V/beta-1 are receptors for fibronectin. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1, and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin, and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin, and CSPG4. Integrin alpha-V/beta-1 is a receptor for vitronectin. Regulates endocytic recycling; may exert its functions by interacting with multiple effector proteins in different complexes; acts as a major regulator of membrane delivery during cytokinesis; together with MYO5B and RAB8A, participates in epithelial cell polarization; together with RAB3IP, RAB8A, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42, and DNMBP, promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation, and lumenogenesis (by similarity); together with MYO5B, participates in CFTR trafficking to the plasma membrane and TF (transferrin) recycling in nonpolarized cells; required in a complex with MYO5B and RAB11FIP2 for the transport of NPC1L1 to the plasma membrane; participates in the sorting and basolateral transport of CDH1 from the Golgi apparatus to the plasma membrane; regulates the recycling of FCGRT (receptor of Fc region of monomeric IgG) to basolateral membranes (by similarity)
Cell cycle (GO:0007049) cytokinesis (GO:0000910); GTP catabolic process (GO:0006184); neuron projection development (GO:0031175); plasma membrane to endosome transport (GO:0048227); protein localization in plasma membrane (GO:0072659); regulation of long-term neuronal synaptic plasticity (GO:0048169); regulation of protein transport (GO:0051223); small GTPase-mediated signal transduction (GO:0007264); vesicle-mediated transport (GO:0016192) ASAH2 N-acylsphingosine amidohydrolase (nonlysosomal ceramidase) 2 (neutral sphingomyelinase)
Hydrolyzes the sphingolipid ceramide into sphingosine and free fatty acid at an optimal pH of 6.5 to 8.5; acts as a key regulator of sphingolipid signaling metabolites by generating sphingosine at the cell surface; acts as a repressor of apoptosis both by reducing C16-ceramide, thereby preventing ceramide-induced apoptosis, and generating sphingosine, a precursor of the antiapoptotic factor, sphingosine 1-phosphate; probably involved in the digestion of dietary sphingolipids in intestine by acting as a key enzyme for the catabolism of dietary sphingolipids and regulating the levels of bioactive sphingolipid metabolites in the intestinal tract Apoptotic process (GO:0006915); ceramide metabolic process (GO:0006672); signal transduction (GO:0007165) 
NF-jB-Induced Activation of Dysferlin Gene Expression
Previous studies from this laboratory have suggested that TNF/TRAF2-mediated activation of NF-jB is responsible for provoking cytoprotective responses in the heart after I/R injury. 11 Previously, we have reported that both RelB and p52
were upregulated in hearts of MHC-TRAF2 LC mice, when compared to LM controls. 19 To determine whether components of noncanonical NF-jB signaling were responsible for the observed increased in dysferlin expression in MHC-TRAF2 LC mouse hearts, we performed a ChIP assay. As shown in Figure 7 , there was a significant 2-fold increase in RelB binding to the dysferlin (variant 1) promoter in MHC-TRAF2 LC hearts, when compared to WT hearts, which was accompanied by significant binding of p50 and p52, which are potential binding partners for RelB. These experiments suggest that TRAF2-mediated activation of NF-KB contributed to increased dysferlin expression observed in MHC-TRAF2 LC hearts. In order to explore the role of dysferlin as a potential mediator of the cytoprotective effects of TRAF2, we first characterized the phenotype of the dysferlin-null (dysferlin À/À) mice employed in these studies. Figure 8A shows that 12-weekold dysferlin À/À mice had no obvious LV phenotype, as assessed by gross morphology and H&E staining. There was, however, a small, but significant, increase in the heart weight/body weight ratio in dysferlin À/À mice, when compared to WT controls ( Figure 8B ). 2D-targeted M-mode echo disclosed no significant differences in LV fractional shortening ( Figure 8C ) or LVDP ( Figure 8D ), LV +dP/dt ( Figure 8E ) and LV ÀdP/dt ( Figure 8F ), or LV dimensions ( Figure 8G through 8I) between dysferlin À/À knockout mice, compared to WT controls.
I/R Injury
Although previous studies in dysferlin-null mice have failed to demonstrate a role for dysferlin in reducing infarct size after acute coronary ligation in vivo, 14 the role of dysferlin after I/R injury (wherein the mechanisms of cell injury are different) is not known. Accordingly, we subjected dysferlin À/À mouse hearts to 30 minutes of global ischemia, followed by 60 minutes of reperfusion. The salient finding shown by Figure 9A is that LV functional recovery after I/R injury was significantly (P<0.001 by ANOVA) worse in dysferlin-null hearts, when compared to WT. Differences in LVDP were evident 20 minutes after reperfusion and remained significantly worse than WT controls 60 minutes after reperfusion (P<0.05/time). Importantly, both myocardial CK release ( Figure 9B ) and degree of uptake of Evans blue dye ( Figure 9C and 9D) were significantly increased (P<0.05 for both) in hearts of I/R-injured dysferlin-null mice, when compared to WT controls. These results are consistent with the thesis that dysferlin-mediated membrane repair is important for main- Figure 6 . Figure 7 . NF-jB chromatin immunprecipitation (ChIP). RelB, p50, p65, and p52 antibodies were used for ChIP on mouse heart chromatin. Presence of NF-jB family members at a jB site in the dysferlin promoter was detected by PCR and expressed as fold change relative to WT controls (n=3). LM indicates littermate; NFjB, nuclear factor kappa B; PCR, polymerase chain reaction; TRAF2, tumor necrosis factor receptor-associated factor 2; WT, wild type.
taining membrane integrity and LV functional recovery after I/R injury.
Effects of Dysferlin on TRAF2-Mediated Cytoprotection After I/R Injury
To determine whether the cytoprotective effects of TRAF2 were mediated, at least in part, through dysferlin, we generated MHC-TRAF2 LC /dysferlin À/À mice and subjected these hearts to I/R injury. The important finding shown by Figure 10A is that the cytoprotective effects of TRAF2 were attenuated significantly in a dysferlin-null background. As shown, functional recovery in MHC-TRAF2 LC /dysferlin À/À mice was significantly less than MHC-TRAF2 LC mice at 10 to 60 minutes (P<0.05/time point) after reperfusion. Furthermore, there was a significant increase in myocardial CK release ( Figure 10B ) and degree of uptake of Evans blue dye (Figure 10C and 10D; P<0.05 for both) in hearts of I/R- Figure 8 . Characterization of dysferlin-null (dysferlin À/À ) mice. Dysferlin À/À and wild-type (WT) control mice were 12 weeks of age. A, Representative photographs of dysferlin À/À and WT control hearts; hematoxylin and eosin-stained cross-sections at the level of the papillary muscle and representative hematoxylin and eosin-stained cross sections at the level of the papillary muscles (9400). B, Heart weight/ body weight ratio (n=6/group) of dysferlin À/À hearts and WT controls. C, Percent LV fractional shortening (% FS) in 12-week-old dysferlin À/À hearts (n=9) and WT controls (n=6). D, Percent LV developed pressure (% LVDP) ex vivo (n=6 hearts/group). E and F, LV +dP/dt and LV ÀdP/dt ex vivo (n=9/group). G, LV enddiastolic dimension (LVEDD), (H) LV posterior wall diameter (LVPWd), and (I) ratio of LV radius to LV wall thickness (r/h). *P<0.05, compared to the respective WT control. BW indicates body weight; HW, heart weight; LV, left ventricle.
injured MHC-TRAF2 LC /dysferlin À/À mice, when compared to MHC-TRAF2 LC mice. A second important finding shown in Figure 10A is that the overall degree of functional recovery in the MHC-TRAF2 LC /dysferlin À/À mice was significantly greater than WT control mice (P<0.001), suggesting that the cytoprotective effects of TRAF2 are not exclusively mediated through dysferlin. To determine whether I/R injury resulted in differential localization of dysferlin in cardiac myocytes from MHC-TRAF LC mouse hearts, compared to LM controls, we performed IHC staining at baseline in na€ ıve hearts and 60 minutes after I/R injury. As shown by the representative photomicrographs in Figure 11 , dysferlin was not immunodetectable in cardiac myocytes from LM controls or MHC-TRAF LC mouse hearts. It contrast, after I/R injury, dysferlin was weakly detectable in the cytoplasm of scattered cardiac myocytes from control hearts, whereas dysferlin immunostaining was easily detectable at the intercalated disks and diffusely throughout the cytoplasm of cardiac myocytes from MHC-TRAF LC mouse hearts, suggesting that TRAF2 signaling resulted in increased dysferlin trafficking to the membrane of MHC-TRAF LC mouse hearts.
Discussion
The results of this study, in which we employed both gain-and loss-of-function approaches to delineate the mechanism(s) for the cytoprotective effects of TRAF2, suggest that TRAF2-mediated upregulation of dysferlin is responsible, at least in part, for the cytoprotective effects of TRAF2 after I/R injury. As shown in Figure 3A , Tg mouse lines with cardiac-restricted overexpression of low levels of TRAF2 (MHC-TRAF2 LC ) had improved LV functional recovery after I/R injury, relative to LM controls, whereas mice with cardiac-restricted overexpression of MHC-TRAF2 DN had decreased LV functional recovery after I/R injury. Decreased functional recovery in MHC-TRAF2 DN mice was accompanied by increased CK release ( Figure 3B ) and Evans blue dye uptake ( Figure 3C and 3D), consistent with increased membrane permeability. Improved functional recovery in MHC-TRAF2 LC mice is associated with decreased CK release and decreased Evans blue dye uptake, consistent with enhanced membrane stability. 11 To delineate the mechanisms for the cytoprotective effects of TRAF2, we performed transcriptional profiling in MHC-TRAF2 LC and MHC-TRAF2 DN mouse hearts. Using this unbiased strategy, we identified a calcium-triggered exocytotic membrane repair protein, termed dysferlin, as a potential candidate cytoprotective gene downstream from TRAF2-mediated signaling ( Figure 4 and Table 2 ). Importantly, dysferlin mRNA and protein were significantly upregulated in MHC-TRAF2 LC mice, whereas dysferlin protein was significantly downregulated in MHC-TRAF2 DN mice ( Figure 6 ). Moreover, dysferlin was immunolocalized to the intercalated disks and diffusely throughout the cytoplasm of cardiac myocytes from MHC-TRAF2 LC mouse hearts after I/R injury, whereas it was weakly detectable in the cytoplasm of WT control hearts ( Figure 11 ). Consistent with our earlier observations, which have implicated an important role for NF-jB signaling in terms of mediating the cytoprotective effects of the TNF-TRAF2-signaling pathway, 11 the ChIP assay identified RelB, p50, and p52 binding in the promoter region of the dysferlin gene ( Figure 7) . Characterization of dysferlin-null mice revealed that they had decreased functional LV recovery, increased CK release, and increased Evans blue dye uptake after I/R injury (Figure 9 ), thus phenocopying the response to I/R injury observed in MHC-TRAF2 DN mice. Finally, breeding MHC-TRAF2 LC mice onto a dysferlin-null background (MHC-TRAF2 LC /dysferlin À/À ) resulted in increased tissue injury, increased Evans Blue dye uptake, and decreased functional recovery, when compared to MHC-TRAF2 LC mice (Figure 10 ), suggesting that dysferlin mediates, at least in part, the cytoprotective effects of TRAF2. Importantly, functional recovery in MHC-TRAF2 LC /dysferlin À/À mice after I/R injury was still significantly greater than observed in WT controls ( Figure 10A ), suggesting that cytoprotective effects of TRAF2 are not mediated exclusively through dysferlin. Indeed, TRAF2 mediates mitophagy through an E3 ligase-dependent mechanism in the adult heart. 21 Although speculative, these results suggest that the cytoprotective effects of TRAF2 may relate to clearance of mitochondria that are damaged after I/R injury.
Dysferlin-Mediated Membrane Repair in the Mammalian Heart
Given that maintenance of plasma membrane integrity is required for cell viability, it is not surprising that cells have evolved a variety of different "emergency repair" mechanisms to facilitate plasma membrane resealing under physiologic and pathophysiologic conditions. This is particularly important for cells residing in mechanically stressful environments, such as cardiac and/or skeletal myocytes. 20, [22] [23] [24] In mammalian cells, plasma membranes reseal spontaneously if the lesion is small (<1 lmol/L). If the membrane lesion is large (>1 lmol/ L), nucleated cells use an active membrane repair process that is based on Ca 2+ -triggered active trafficking of cytoplasmic vesicles to the site of membrane damage with subsequent fusion of vesicles with the plasma membrane (exocytosis), thereby creating a "patch" of new membrane across the gap in the plasma membrane. The process of active membrane fusion during exocytosis requires several membrane proteins, including SNARE proteins, 25 synaptotagmins, 26 and a recently described muscle-specific TRIM protein, MG53, that is important in sarcolemmal repair in ischemic preconditioning. 27 Recently, a family of proteins termed "ferlins" has been shown to play an important role in membrane repair by facilitating Ca 2+ -mediated trafficking of vesicles to the site of membrane injury. The ferlin family consists of four different highly conserved genes that encode dysferlin, myoferlin, otoferlin, and Fer1L4 (reviewed previously 25 ). Dysferlin is a 273 kDa type II transmembrane protein that is enriched in skeletal and cardiac muscle. 20 Mutations in dysferlin lead to three distinct muscular dystrophies ("dysferlinopathies"): limb-girdle muscular dystrophy type 2B; 28 Miyoshi myopathy; 28 and distal myopathy with anterior tibialis onset.
Although onset of dilated cardiomyopathy is extremely rare in dysferlinopathies, %50% of patients develop mild structural (increased myocardial fibrosis) and functional (diastolic dysfunction) cardiac abnormalities. 29, 30 These findings are consistent with experimental studies that have shown that aging dysferlin-deficient mice develop progressive myocardial fibrosis by 10 to 12 months of age, suggesting an important role for membrane repair mechanisms in aging hearts. 14, 31 Relevant to the present study, dysferlin deficiency has been implicated in the development of a dilated cardiomyopathic phenotype after adrenergic and/or mechanical stress.
14, 30 Han et al. demonstrated increased cardiac myocyte membrane permeability (increased Evans blue dye uptake) and progressive LV dysfunction in exercising dysferlin-null mice. Although these researchers did not demonstrate a role for dysferlin in reducing Figure 11 . Dysferlin immuohistochemical staining in littermate controls and MHC-TRAF LC mouse hearts.
In na€ ıve hearts, dysferlin was not immunodetectable in cardiac myocytes from littermate controls (A) or MHC-TRAF LC mouse hearts (B). In contrast, after I/R injury, dysferlin was weakly detectable in the cytoplasm of scattered cardiac myocytes from control hearts (B and C). As shown by arrows, dysferlin immunostaining was easily detectable at the intercalated disks (E) and diffusely throughout the cytoplasm (F) of cardiac myocytes from MHC-TRAF LC mouse hearts, suggesting that TRAF2 signaling resulted in increased dysferlin trafficking to the membrane of the MHC-TRAF LC mouse heart. I/R indicates ischemia reperfusion; TRAF2, tumor necrosis factor receptor-associated factor 2.
infarct size after acute coronary ligation, they did not examine the role of dysferlin in I/R injury, wherein the mechanisms of cell injury are different. Our results are in agreement with these earlier studies that have demonstrated an important role for dysferlin-mediated membrane repair during mechanical stress 14 and extend these observations by demonstrating the importance of membrane resealing as a critical component of the cytoprotective effects of inflammatory signaling after I/R injury. These results are also concordant with our earlier in vitro observations, wherein we demonstrated that TNF-mediated signaling through TNFR1 or TNFR2 preserved sarcolemmal membrane integrity (calcium influx and lactic dehyrogenase release) in isolated cardiac myocytes that were subjected to hypoxia reoxygenation injury. 5 Although the present study did not delineate the mechanism(s) for the cytoprotective role of dysferlin during I/R injury, it bears emphasis that the exact mechanisms responsible for dysferlin-mediated membrane repair are incompletely understood. 32 Moreover, these studies were conducted ex vivo, which excludes the effects of infiltrating inflammatory cells that could also affect innate immune signaling, Accordingly, it will be important, in future studies, to further delineate the interacting protein partners for dysferlin in MHC-TRAF2 LC mice, as well as extend these observations to studies in vivo Finally, we cannot exclude the formal possibility that the deleterious effects observed in MHC-TRAF2 DN mice after I/R injury were nonspecific, and were secondary to high levels of expression of the transgene, as has been reported for inert proteins that have been overexpressed in the heart.
Conclusions
The results of this study demonstrate, for the first time, that TRAF2-mediated signaling confers cytoprotection in the heart, at least in part, through upregulation of dysferlin, a calciumtriggered exocytotic membrane repair protein. Although the innate immune system has been implicated in maintaining "barrier function" in the skin, gastrointestinal system, and trachea in vertebrate species, 33, 34 these observations have focused predominately on activation of the adaptive immune system by the innate immune system in response to disruption of the epithelial barrier. Our results extend this conceptual paradigm and suggest that one of the important functions of innate immune activation in the heart in response to tissue injury is preservation and maintenance of the physical barrier between the extra-and intracellular environment through enhanced and/or facilitated sarcolemmal repair, thereby preventing calcium-induced activation of cell death machinery, loss of cytosolic constituents vital to cell function, as well as preserving the electrochemical gradient across the sarcolemma that is required for membrane excitability and myocyte contraction. Consistent with this thesis, both gain-and loss-of-function studies have shown that TNF and TNF receptors are required for preservation of epidermal barrier function in mice. 35 This point of view is also consistent with the "danger" model of immunity, which proposes that healthy tissue induces tolerance (eg, preconditioning), whereas unhealthy tissue stimulates the adaptive immune system, which would be activated by release of damage-associated molecular patterns. 36 Given that loss of dysferlin-mediated membrane repair attenuated, but did not abrogate, the cytoprotective effects of TRAF2-mediated signaling, it will be important, in subsequent studies, to determine whether additional plasma membrane proteins that were identified by our screening strategy contribute to maintaining sarcolemmal repair after I/R injury.
